Bioherent, a biotechnology startup specializing in the development of in vitro diagnostic devices based on photonic biosensors and nanotechnology, has announced the incorporation of Axon Partners Group as a new investment partner, co-investing alongside Bullnet Capital and CDTI-Innvierte, the company's initial investors.
The joint investment from Axon, Bullnet, and CDTI will allow Bioherent to advance the clinical validation of its platform for diagnosing antibiotic allergies using non-invasive, high-sensitivity methods, as well as scale its manufacturing processes and take the first steps toward commercialization in Europe.
“The addition of Axon not only provides us with strategic financial backing, but also with a valuable network of knowledge and expertise that is key to Bioherent's growth,” says Yara Aceta, CEO of Bioherent. “Together, we are taking a solid step toward a new paradigm in the diagnosis of drug hypersensitivity—an unmet clinical need.”
Through this partnership, Bioherent reinforces its commitment to developing accurate, accessible, and rapid diagnostic tools that help reduce the overdiagnosis of beta-lactam allergies, one of the contributing factors to the growing issue of antimicrobial resistance.
“We see in Bioherent a unique technological proposition, with a solid scientific foundation and clear clinical application,” says Macarena González, Head of Investments in Andalusia at Axon Partners Group. “We believe strongly in the platform's potential to transform disease diagnostics. With Bioherent, we’re contributing to the decentralization of diagnostic access and the promotion of more personalized, efficient, and sustainable healthcare systems.”
Javier Ulecia and Miguel del Cañizo, founding partners of Bullnet Capital, add: “We are very pleased to have our colleagues at Axon join us in this new stage of Bioherent. We hope this is the first of many future co-investments with them in other Andalusian companies.”
Bioherent is an early-stage company based in Málaga focused on developing innovative solutions for clinical diagnostics. Its technology combines high-precision optical biosensors with nanotechnology-functionalized surfaces, enabling the detection of immune reactions with unprecedented sensitivity and automation, using minimal sample volumes.
Axon is a global investment and consulting firm specializing in technology and innovation, with approximately €700 million in assets under management and a presence across Europe, the Americas, and EMEA. Founded in 2006, it has more than 90 professionals and offices in Madrid (headquarters), Seville, Bogotá, Milan, and Istanbul. The investment in Bioherent is made through Axon Desarrollo Andalucía, an R&D&I Portfolio Fund backed by the Andalusian Regional Government and the European Investment Bank, aimed at promoting research, development, innovation, and digitalization in Andalusia, within the framework of the European Regional Development Fund (ERDF).
Bullnet Capital is an independent Spanish venture capital firm focused on high-tech companies (software, electronics, semiconductors, photonics). Established in 2002, it manages a total of €140 million across multiple investment vehicles. To date, Bullnet Capital has invested in thirty early-stage Spanish companies and maintains its investment philosophy of adding value and contributing actively to the day-to-day operations of its portfolio companies.
cloud technology axon
Xcalibur Smart Mapping, recognised as the global leader in airborne...
